What is Byetta?
Byetta (exenatide) is an injectable type 2 diabetes drug marketed by Amylin Pharmaceuticals, Inc. and Eli Lilly & Company. This diabetes medication was approved by the FDA in 2005 as an adjunct to diet and exercise to improve glycemic control. Byetta is not used for treatment of patients with type 1 diabetes.
The FDA issued its first warning in 2007 about Byetta being associated with acute pancreatitis, which is severe inflammation of the pancreas. Symptoms include persistent severe abdominal pain that can radiate to the back, which may or may not be accompanied by nausea and vomiting.
In 2008 the FDA warned that it had received additional reports about fatal and non-fatal hemorrhagic pancreatitis or necrotizing pancreatitis in patients using Byetta, which involved massive bleeding or tissue injuries in the pancreas.
Also in 2008 the European Medicines Agency (Europe's equivalent to the FDA) issued a warning about case reports of renal insufficiency and kidney failure, some which required dialysis, that involved Byetta use. This was followed by a 2009 FDA warning about reports of altered kidney function in Byetta patients.
October 2009 FDA Letter About Byetta Demands That Several Safety Studies Be Done By Drug Company
This letter from the FDA warns that there are several serious side effects that the FDA has concerns about. Among these side effects are potentially life threatening conditions and diseases such as pancreatitis, pancreatic cancer, thyroid Neoplasm, and acute renal failure.
FDA Alert About Diabetes Medication Byetta Being Linked To Acute Pancreatitis Issued In October 2007
The FDA issued a MedWatch alert back in October 2007 reporting that it had received 30 reports of acute pancreatitis in patients taking Byetta (exenatide) since this diabetes medication was first approved by the agency in April 2005. Further, as part of this FDA warning, the Byetta package insert, or label, was changed to include information about pancreatitis in the "Precautions" section.
Diabetes Medication Byetta Has Been Related To Hemorrhagic Pancreatitis And Necrotizing Pancreatitis
Since October 2007 the FDA has received reports of six cases of hemorrhagic pancreatitis or necrotizing pancreatitis associated with the use of Byetta (exenatide). In August 2008 the FDA issued a MedWatch email alert regarding this startling information.
Byetta Gets New Warning About Severe Kidney Side Effects, Including Acute Renal Failure
In early November 2009 the FDA announced its approval of the revised Byetta package insert which will now include safety information about the numerous case reports of kidney-related side effects, including kidney failure and renal insufficiency.
Byetta Class Actions
We believe that people who suffered a serious injury which may have been caused by the use of Byetta are better served when an individual lawsuit is filed on their behalf. A serious injury case should not be filed as part of any Byetta class action together with the claims of many other people who may have had different injuries possibly caused by this type 2 diabetes drug.
Legal Compensation for Byetta Injuries
If you experienced serious side effects or adverse reaction which may have been caused by the use of Byetta, you may have a claim for legal compensation. Legal compensation claims involving injuries which may have been caused by the use of Byetta are made by filing a lawsuit in court. All states have statutes of limitations that determine the time period allowed to file a Byetta lawsuit.
Free Byetta Case Evaluation
The information you provide to us for this Free Case Evaluation will be treated as strictly confidential. You will get a reply from us no later than the next business day. Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit. We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.
Cancer of The Pancreas: Possible Side Effect For Diabetics Who Use Byetta, Januvia, Or Victoza?
Diabetes Doctors And Drug Safety Watchdog Group Express More Concern Than Ever Following June 2013 BMJ Medical Journal Article
SUMMARY: We will start with the most recent development, as reported June 11, 2013 on the Medscape web site, "ADA: Independent Review of Incretins and Pancreatitis, Cancer".
The day before, June 10, Medscape published this related article, "BMJ Digs Deep Into Incretins and Pancreatic Cancer Debate".
And lastly, from "Has Pancreatic Damage From Glucagon-Suppressing Diabetes Drugs Been Underplayed? -- U.K. investigators cite growing safety concerns", published on the PTCommunity.com site.
[Read this article in full at original source]
Earlier Byetta articles by Tom Lamb on the Drug Injury Watch blog:
Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, And Victoza -- Little Is Known About Long-Term Effects
Byetta And Januvia: More Debate About The Possible Increased Risk Of Pancreatitis, Pancreatic Cancer, And Thyroid Cancer
Acute Pancreatitis Case Associated With Victoza Use, Similar To Byetta And Januvia Case Reports
Gastroenterology Medical Journal Withdraws Januvia / Byetta Article Due To Letters From Drug Companies
New Extensively Documented Case Report About Patient With Probable Byetta-Induced Pancreatitis
FDA Wants Studies Done On Byetta Safety, With Focus On Pancreatitis, Pancreatic Cancer, Thyroid Neoplasm, And Acute Renal Failure
Diabetes Drug Byetta Linked To Altered Kidney Function And Cases Of Renal Failure
A Review Of Recent Research On Issue Of Whether Januvia Can Cause Pancreatitis
Case Report Of Woman With Likely Byetta-Induced Acute Pancreatitis
Warnings About Byetta Associated With Risk Of Severe Pancreatitis And Renal Failure
August 2008: Byetta Associated With Hemorrhagic Pancreatitis And Necrotizing Pancreatitis
More Information About Reports Of Byetta Use Being Linked To Acute Pancreatitis
December 2007 FDA "Patient Safety News" Videos For Doctors Online
FDA Alerts Doctors About Diabetes Drug Byetta And Acute Pancreatitis Reports
All content by attorney Tom Lamb